Aug. 14 at 8:58 PM
$SLS the
$ABVX $5 to
$148 run will look Anemic compared to whats about to happen Here... ANY DAY.
SLS is about to announce phase 3 registrational trial results, 6+ years in the making, giving GPs the Fda green light to treat upwards of 50,000 AML Remission Patients each year - and Generate TENS of BILLIONS of dollars in Real Revenue - that is worth every nickel of
$50B to big pharm.
Do the Math
+ 2X 3X 4X survival advantage for CR2/3 Patients, combined w:
• GPS Pristine Safety Profile
• Prior Phase 2 Results in CR1 that are Better than Transplant
• EAP for CR1 and post Transplant Patients
REQUIRE Gps Value include the CR1 / Post Transplant Market.
100,000 Patients currently in remission who'll benefit from GPS right out of the Gate.
• FDA Already signed off on TypeC Manufacture, low cost/high margin
• FDA/EU Orphan / Fast Track / Rare Priority Review
• IP rights into 2037 + Next Gen GPS+ Immunotherapy
• Ease of administration, in home will Set Records for Patient Uptake Rates.
